The Drug Was Worth Billions Until the Patent Expired on a Tuesday
A branded drug can lose most of its revenue within months of patent expiry as generic copies enter. The cliff is predictable to the day, which shapes how the whole industry is run.
The Cliff
A pharmaceutical company that develops a successful drug is granted a patent giving it exclusive rights to sell it for a period. During that time it can price the drug to recover the enormous cost of development, most of which was spent on the far larger number of candidates that failed.
When the patent expires, other manufacturers can produce chemically identical generic versions. Because they did not bear the development cost and compete only on price, the generic sells for a fraction of the branded price, and it captures the large majority of volume quickly.
The revenue does not decline. It falls off a cliff, on a date known years in advance, and there is very little the company can do to stop it.
How Fast and How Far
The speed and severity depend on the market and the number of generic entrants, but the pattern is stark. Within a year of expiry, a branded drug can lose the majority of its revenue, sometimes the overwhelming majority.
| Stage | Price | Branded volume |
|---|---|---|
| Under patent | High | Full market |
| First generic enters | Falls | Begins to shift |
| Multiple generics | Collapses toward cost | Small remainder |
Once several generics compete, the price approaches the cost of manufacturing, which for many drugs is very low. The branded company often chooses not to compete at that price at all, effectively conceding the market rather than destroying its own pricing elsewhere.
Why the Whole Industry Is Shaped by It
Because the cliff is certain and its timing is known, the branded pharmaceutical business is organised around it. The company knows years ahead exactly when a major product revenue will collapse, which creates a permanent need to replace that revenue.
This drives the industry defining behaviours. Heavy research spending to develop the next drug before the current one expires. Large acquisitions of companies with promising pipelines when internal research falls short. And intense focus on the patent cliff, the calendar of when the company major products lose protection, which analysts track closely because it determines future revenue with unusual certainty.
Strategies to Delay the Cliff
Companies deploy various tactics to extend exclusivity, some legitimate and some contested.
Reformulation. Developing a new version, an extended release form or a combination, that carries its own patent and encouraging patients to switch to it before the original expires. This is legal and criticised as evergreening when the new version offers little genuine benefit.
Authorised generics. The branded company launches its own generic at expiry, capturing some of the generic market it would otherwise lose entirely.
Settlements with generic makers. Agreements that delay a generic entry, which have attracted antitrust scrutiny where the branded company effectively pays a competitor to stay out.
Switching to biologics. Large molecule drugs are far harder to copy exactly, so their equivalents, called biosimilars, enter more slowly and less completely, softening the cliff.
The Biologic Difference
That last point is significant enough to have redirected the industry. Traditional small molecule drugs are simple chemicals that can be copied precisely, producing the sharp cliff. Biologics, produced in living cells, are complex and difficult to replicate exactly.
Their copies, biosimilars, are similar rather than identical, face a more demanding approval process, and do not achieve the automatic substitution that lets a generic capture a market overnight. The erosion is slower and less complete, which makes biologics commercially attractive beyond their therapeutic value, and part of why the industry has shifted toward them.
Why the System Is Designed This Way
The cliff is not a flaw. It is the intended result of the patent bargain. Society grants a temporary monopoly to reward and fund the risk of drug development, then removes it so that the medicine becomes cheap and widely available once the reward period ends.
The generic price collapse is the public benefit of the system working. The branded company recovered its investment during exclusivity, and afterward the drug is available at close to cost forever. Tensions arise around the tactics used to delay the transition, which push against the point at which the public is meant to receive the benefit.
The Bottom Line
A branded drug loses most of its value on a known date when generic competition arrives, and that certainty shapes the entire branded pharmaceutical industry around continually replacing revenue before it disappears. The cliff is the patent bargain working as designed, granting temporary reward then delivering cheap medicine. The contested ground is the set of tactics used to postpone the transition, and the shift toward biologics is partly a move toward products whose copies erode the revenue more gently.